The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | Immunotherapy trial updates in NSCLC from ESMO 2020
Roy Herbst, MD, PhD, FACP, FASCO, Yale University, New Haven, CT, discusses three abstracts presented at the European Society of Medical Oncology (ESMO) 2020 virtual congress, including 5-year overall survival data from the KEYNOTE-024 (NCT02142738) study evaluating pembrolizumab versus chemotherapy in non-small cell lung cancer (NSCLC), the results from the EMPOWER-Lung 1 study investigating cemiplimab monotherapy and finally, the first analysis of the PIONeeR study (NCT03833440) in NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
